Mithra’s exclusivity on Estetrol applications extended to 2036 in Europe

Thanks to a new patent relating to Estetrol applications, Mithra secures its future results. A similar process is underway for the US market.

Liège, Belgique, 30 novembre 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has been granted a new patent by the European Patent Office (EPO) relating to various pharmaceutical compositions containing Estetrol (E4) and their manufacturing process. In doing so, Mithra consolidates its exclusivity for the use of E4 in a wide range of indications such as the treatment of hormone-dependent cancers (breast and prostate in particular), dermatology, neuroprotection, dysmenorrhea and emergency contraception